SEC Form 4 · accession 0001209191-15-040810
HYPERION THERAPEUTICS INC · HPTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Theodore R Schroeder
Director
Period of report
May 7, 2015
Accepted (ET)
May 8, 2015 · 7:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386858
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 7, 2015 | U | 617 | $46.00 | D | 0 | D | |
| Common StockF2 | May 7, 2015 | D | 3,083 | $46.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $24.57 | May 7, 2015 | D | 6,800 | D | — | Aug 12, 2024 | Common Stock | 6,800 | 0 | D |
Explanation of responses
- F1Shares that were tendered pursuant to the offer from Horizon Pharma plc ("Horizon") to acquire shares of the issuer.
- F2Restricted stock units covering shares of the issuer common stock that will be cashed-out and cancelled in connection with the merger of the issuer and Horizon (the "Merger").
- F3Options to acquire shares of issuer common stock that will be cashed-out and cancelled in connection with the Merger.